|
|
||||||||
J Thorac Cardiovasc Surg 2005;129:1203
© 2005 The American Association for Thoracic Surgery
Letters to the Editor |
University Hospitals of Cleveland Cardiothoracic Surgery 11,100 Euclid Ave Cleveland, OH 44106
Thank you for your interest in our publication entitled "Axillary artery cannulation for cardiopulmonary bypass reduces cerebral microemboli." We are confident that our conclusion, that axillary cannulation reduces cerebral microemboli, is supported by our experimental evidence. We apologize for any lack of clarity with our experimental design. We agree that the distribution pattern of the microspheres might be influenced by the pump flow rate, microsphere injection rate, shape of the aorta, location of the injection, and location of the cardiopulmonary bypass cannulation site. Using each animal as its own control enabled us to provide constant conditions for each variable, with the only difference being the cannulation site.
Our microsphere injection method was consistent for each animal. The only variable was the cannulation site for cardiopulmonary bypass. The pump flow rate was constant during the 2 cannulation techniques within each animal, although the pump rate did vary from 1.9 to 3.4 L · min1 · m2 among animals to maintain constant pressure among animals. Five million microspheres (2.5 x 106 microspheres/mL) were injected over 1 minute.
Larger microspheres have been used to induce infarction or ischemia and might have been preferred if that was our intention. We were exclusively interested in the distribution of the spheres and found no evidence that the distribution of 50-µm spheres would have, in our model, altered our impressive results. Atheroemboli range in size, with the most numerous being the smallest.1 We used 15-µm spheres, as has been done before in similar investigations.2
We agree with your suggestion that further characterization of the flow pattern through particle-imaging techniques will provide additional evidence as to the superior ability of axillary cannulation to provide cerebroprotection, and we plan to do so in the future to further corroborate the vastly reduced stroke rate we have observed when axillary perfusion was used in our patients with high-risk aortas.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |